Loading…
Lobbying Spend
—
Filings
23
Firms Hired
1
Active Period
2019–2023
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.
2019 · first_quarter · Firm: GRAY GLOBAL ADVISORS, LLC
Issues related to the Orphan Drug Act H Res 242 "Affirming the importance of the Orphan Drug Act" The SPIKE Act; Prescription Drug Pricing Classification
Client expense: — · Firm income: $10,000
Matched citations: H Res 242
Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.
2019 · second_quarter · Firm: GRAY GLOBAL ADVISORS, LLC
Issues related to the Orphan Drug Act H Res 242 "Affirming the importance of the Orphan Drug Act" The SPIKE Act; Prescription Drug Pricing Classification
Client expense: — · Firm income: $90,000
Matched citations: H Res 242
Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.
2019 · first_quarter · Firm: GRAY GLOBAL ADVISORS, LLC
Issues related to the Orphan Drug Act H Res 242 "Affirming the importance of the Orphan Drug Act" The SPIKE Act; Prescription Drug Pricing Classification
Client expense: — · Firm income: —
Matched citations: H Res 242
Source: Senate LDA